Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Louis D Saravolatz

Showing results (1-10 of 67) with videos related to

Pageof 7
Sort By:
Infectious Diseases in Clinical Practice (Baltimore, Md.)|September 20, 2021
Early Use of Remdesivir: A Good StartLouis D Saravolatz
International Journal of Antimicrobial Agents|September 18, 2010
In vitro activity of ceftobiprole against meticillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA)Louis D Saravolatz, Joan Pawlak, Leonard B Johnson, et al.
Diagnostic Microbiology and Infectious Disease|October 28, 2018
VISA-Daptomycin non-susceptible Staphylococcus aureus frequently demonstrate non-susceptibility to TelavancinLouis D Saravolatz, Joan Pawlak
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 15, 2003
Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolonesLouis D Saravolatz, James Leggett
The Journal of Antimicrobial Chemotherapy|October 27, 2012
Rilpivirine: a new non-nucleoside reverse transcriptase inhibitorMamta Sharma, Louis D Saravolatz
Jac-Antimicrobial Resistance|July 5, 2024
Rhodomyrtone: a new anti-<i>Staphylococcus aureus</i> agent against resistant strainsLouis D Saravolatz, Joan Pawlak
The Journal of Antimicrobial Chemotherapy|November 14, 2022
In vitro activity of fosfomycin alone and in combination against Staphylococcus aureus with reduced susceptibility or resistance to methicillin, vancomycin, daptomycin or linezolidLouis D Saravolatz, Joan Pawlak
JAMA|January 10, 2025
What Is Bird Flu?Louis D Saravolatz, Preeti N Malani
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 2, 2020
The American Board of Internal Medicine's New Longitudinal Assessment Option and What It Means for Infectious Disease SpecialistsGeorge M Abraham, Louis D Saravolatz
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 31, 2018
Delafloxacin: A New Anti-methicillin-resistant Staphylococcus aureus FluoroquinoloneLouis D Saravolatz, Gary E Stein
Pageof 7

Showing results (1-10 of 67) with videos related to

Sort By:
Pageof 7
Infectious Diseases in Clinical Practice (Baltimore, Md.)|September 20, 2021
Early Use of Remdesivir: A Good StartLouis D Saravolatz
International Journal of Antimicrobial Agents|September 18, 2010
In vitro activity of ceftobiprole against meticillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA)Louis D Saravolatz, Joan Pawlak, Leonard B Johnson, et al.
Diagnostic Microbiology and Infectious Disease|October 28, 2018
VISA-Daptomycin non-susceptible Staphylococcus aureus frequently demonstrate non-susceptibility to TelavancinLouis D Saravolatz, Joan Pawlak
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 15, 2003
Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolonesLouis D Saravolatz, James Leggett
The Journal of Antimicrobial Chemotherapy|October 27, 2012
Rilpivirine: a new non-nucleoside reverse transcriptase inhibitorMamta Sharma, Louis D Saravolatz
Jac-Antimicrobial Resistance|July 5, 2024
Rhodomyrtone: a new anti-<i>Staphylococcus aureus</i> agent against resistant strainsLouis D Saravolatz, Joan Pawlak
The Journal of Antimicrobial Chemotherapy|November 14, 2022
In vitro activity of fosfomycin alone and in combination against Staphylococcus aureus with reduced susceptibility or resistance to methicillin, vancomycin, daptomycin or linezolidLouis D Saravolatz, Joan Pawlak
JAMA|January 10, 2025
What Is Bird Flu?Louis D Saravolatz, Preeti N Malani
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 2, 2020
The American Board of Internal Medicine's New Longitudinal Assessment Option and What It Means for Infectious Disease SpecialistsGeorge M Abraham, Louis D Saravolatz
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 31, 2018
Delafloxacin: A New Anti-methicillin-resistant Staphylococcus aureus FluoroquinoloneLouis D Saravolatz, Gary E Stein
Pageof 7